Core Viewpoint - Changchun Jinsai Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with ALK-Abelló A/S to jointly develop and commercialize allergen-specific immunotherapy products in China, enhancing the market presence of desensitization treatments in the region [1][2]. Group 1: Partnership Details - The collaboration includes two allergen-specific immunotherapy products and one skin prick test kit developed by ALK [3]. - Jinsai Pharmaceutical will have exclusive rights to sell ALK's subcutaneous dust mite allergen preparation (Andorra), skin prick test kit (Anci), and sublingual tablet (ACARIZAX) in mainland China until December 31, 2039 [3]. - Starting from October 1, 2025, Jinsai will take over the sales and marketing of ALK's already launched products in mainland China and will collaborate on the clinical development of ACARIZAX [3]. Group 2: Market Potential - The global allergy immunotherapy market is projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 9.5% [3]. - China has the largest population of dust mite allergy patients globally, yet the market for allergy immunotherapy remains underdeveloped, with fewer than 1 million patients currently receiving desensitization treatment [3]. Group 3: Product Significance - Desensitization therapy is recognized as the only treatment that can potentially alter the natural course of allergic diseases [4]. - Andorra is a well-established desensitization product with unique efficacy benefits, while ACARIZAX is an innovative sublingual tablet that has been approved in multiple countries [4]. - The partnership aims to enhance the accessibility of these breakthrough products to meet the significant unmet clinical needs in China, where the penetration rate of desensitization therapy is below 4% [7].

Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [2] - The partnership includes exclusive rights for Changchun Jin Sai Pharmaceutical Co., Ltd. to market three products developed by ALK in mainland China [2] Company Summary - Changchun High-tech's subsidiary, Changchun Jin Sai Pharmaceutical, will work with ALK-Abelló A/S on AIT products targeting house dust mites (HDM) [2] - The collaboration aims to leverage ALK's expertise in immunotherapy to enhance product offerings in the Chinese market [2] Industry Summary - The partnership signifies a growing trend in the immunotherapy sector, particularly in addressing allergic conditions in China [2] - The exclusive rights to market ALK's products may strengthen Changchun High-tech's position in the competitive pharmaceutical landscape [2]

Group 1 - The core point of the article is that Changchun High-tech (000661) has entered into a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China [1] - Changchun Jin Sai Pharmaceutical, a subsidiary of Changchun High-tech, will have exclusive rights to three ALK-developed products in mainland China, including subcutaneous allergen preparations, skin prick test kits, and sublingual tablets [1] - The collaboration agreement grants Changchun Jin Sai Pharmaceutical exclusive rights until December 31, 2039, and involves an upfront payment of €32.7 million for the commercialization rights of the three products [1]

Core Viewpoint - Changchun High-tech (000661) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights for three products in the mainland market [1] Group 1: Partnership Details - The partnership involves Changchun High-tech's subsidiary, Jinsai Pharmaceutical, which will pay an upfront fee of €32.7 million for the collaboration [1] - Jinsai Pharmaceutical will also make a milestone payment of €40 million based on the clinical trial regulatory approval progress for the sublingual tablet (ACARIZAX) for adults, adolescents, and children in China [1] - Future payments of up to €105 million may be made depending on the sales performance of the products in the Chinese market [1]

Core Viewpoint - Changchun High-tech announced a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights to three of ALK's independently developed products in mainland China [1] Group 1 - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., will work with ALK on the AIT products [1] - The collaboration focuses on the development and commercialization of HDM allergen-specific immunotherapy products in the Chinese market [1] - The agreement includes exclusive agency rights for three ALK-developed products within mainland China [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech, will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - The collaboration grants Changchun Jinsai exclusive rights to three ALK-developed products in mainland China, including subcutaneous HDM allergen preparations (Acarizax), skin prick test kits (Acarizax), and sublingual tablets (ACARIZAX®) [1] - The partnership agreement is valid until December 31, 2039, and Changchun Jinsai will pay an upfront fee of €32.7 million for the commercialization rights [1]

Group 1 - The core point of the article is that Changchun High-tech (SZ 000661) announced a collaboration with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT) products during its board meeting on September 17, 2025 [1] - For the first half of 2025, the revenue composition of Changchun High-tech was as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from services [1] - As of the report date, the market capitalization of Changchun High-tech was 50.5 billion yuan [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-128 长春高新技术产业（集团）股份有限公司 关于子公司与丹麦 ALK-Abelló A/S 公司 达成变应原特异性免疫治疗（AIT）产品合作的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股子公司 ——长春金赛药业有限责任公司（以下简称"金赛药业"）与丹麦 ALK-Abelló A/S 公司（以下简称"ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中 国联合开发并商业化 ALK 的屋尘螨（HDM）变应原特异性免疫治疗产品，并获得 ALK 自主开发的 3 款产品在中国大陆（以下简称"合作地域"）范围内的独家代 理权益。 一、许可产品基本信息 本次合作产品为 ALK 自主开发的 3 款产品，包括 2 款变应原特异性免疫治疗 产品和 1 款用于螨变应原检测的皮肤点刺试剂盒： ①屋尘螨变应原制剂（安脱达）：一款在中国已上市销售的皮下注射免疫治 疗屋尘螨变应原制剂； ②尘螨变应原舌下片（ACARIZAX®）：为全球首款被批准用于 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-127 长春高新技术产业（集团）股份有限公司 第十一届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、经长春高新技术产业（集团）股份有限公司（以下简称"公司"）半数 以上董事同意，公司第十一届董事会第十三次会议于 2025 年 9 月 13 日以微信方 式发出会议通知。 2、本次董事会于 2025 年 9 月 17 日 14 时以现场结合通讯方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、会议由董事长姜云涛先生主持，公司高级管理人员列席了本次会议。 经与会董事认真讨论，本次会议审议通过了《关于子公司与丹麦 ALK-Abelló A/S 公司达成变应原特异性免疫治疗（AIT）产品合作的议案》。 表决结果：9 票同意，0 票反对，0 票弃权。 子公司长春金赛药业有限责任公司与丹麦 ALK-Abelló A/S 公司（以下简称 "ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中国联合开发并商 业化 ALK ...

Core Viewpoint - Changchun High-tech announced a collaboration between its subsidiary Jinsai Pharmaceutical and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Jinsai Pharmaceutical will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - Jinsai Pharmaceutical has secured exclusive agency rights for three products independently developed by ALK within mainland China [1] Group 2: Financial Terms - An initial payment of €32.7 million will be made by Jinsai Pharmaceutical [1] - Jinsai Pharmaceutical will pay a milestone payment of €40 million upon regulatory approval for clinical trials of the ACARIZAX sublingual tablet for adults, adolescents, and children in China [1] - Future sales performance of the products in the Chinese market may lead to additional milestone payments of €105 million [1]